arrow
H

Han W. Tun

Dana-Farber Cancer Institute
H指数:29
被引数:3,803

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort Study

Castleman疾病亚型特异性结局与管理的综合分析:一项20年队列研究

2025-12-290
OAAI
ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION

复发/难治性原发性中枢神经系统淋巴瘤患者对新型EMAVUSERTIB(IRAK4I)和BTKI联合治疗反应的遗传突变谱和中枢神经系统药代动力学分析

2025-11-010
OAAI
PRELIMINARY SAFETY AND EFFICACY OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS

初步安全性及有效性:Emavusertib (CA-4948) 联合 Ibrutinib 在复发/难治性原发性中枢神经系统淋巴瘤患者中的应用

2025-11-010
OAAI
The Role of Radiation Therapy in the Management of Gray Zone Lymphoma

放射治疗在Gray Zone Lymphoma管理中的作用

2025-10-140
PRE
Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor

初步评估Emavusertib (CA-4948)联合Ibrutinib在既往接受过BTK抑制剂治疗的原发性中枢神经系统淋巴瘤复发/难治性患者中的安全性与有效性

BLOOD
IF23.1
2024-11-051
PRE
Addition of MAPK inhibitors to prime and sensitize poorly differentiated thyroid cancers as a strategy to improve TSHR-CART cell therapy antitumor activity
2023-04-040
PRE
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study
2023-03-075
PRE
Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy

利妥昔单抗和糖皮质激素对嵌合抗原受体T细胞治疗后晚期血细胞减少的影响

2022-10-014
OAAI
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018)
2022-07-067
OAAI